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Abstract: In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of
transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The
World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus
spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targetedtherapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for
patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARSCoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This
review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization
assays.
Key words: SARS-CoV-2, COVID-19, neutralizing antibodies, human monoclonal antibody, display technologies, human scFv,
neutralizing assays, animal models

1. Introduction
In December 2019, in Wuhan City of Hubei ProvinceChina, a novel coronavirus (coronaviridae family) was
detected. Coronaviruses are members of a wide group of
viruses causing various diseases ranging from flu to more
extreme diseases like severe acute respiratory syndrome
(SARS) and Middle East respiratory syndrome (MERS).
The new virus called SARS-CoV-2 differed from others
by its unexpectedly rapid spread due to a high rate of
transmission from human to human.
There are currently no approved targeted therapies
available for COVID-19. Researchers worldwide are
exploring COVID-19 prevention strategies and therapeutic
options, including convalescent plasma, monoclonal
antibodies, vaccines, peptides, interferon, small molecule
drugs, as well as exploring the repurposing of proven drugs
(Li and De Clercq, 2020). Vaccination may provide a strong
and sustainable protection, however, vaccine development
is a long and challenging process, and vaccination is only
useful in a preventive environment. On the other hand, an
antibody-based therapy can provide immediate effect for
patients.
Neutralizing antibodies (NAbs) target viral surface
proteins for blocking the attachment of virus to host

cell (Klasse, 2014). Therefore, in SARS-CoV-2 studies,
amongst all structural proteins, neutralizing antibodies
primarily target the S (spike) protein, which mediates entry
into cells. The structural protein S is a transmembrane
glycoprotein that has 2 functional subunits: the subunit
S1 that is involved in cell attachment and the subunit S2
that mediates cell membrane fusion (Siu et al., 2008).
S1 also breaks down into 2 domains, a receptor-binding
domain (RBD) and an N-terminal domain (NTD). The S
protein binds the human angiotensin converting enzyme
2 (ACE2) receptor through its S1 subunit. SARS-CoV-2
appears to be using the same receptor, ACE2, for cell entry
as SARS-CoV with a 10 to 20-fold higher affinity (Wrapp
et al., 2020). As shown in Table, all currently developed
anti-SARS-CoVNAbs target the S protein, predominantly
target the RBD, while some target regions in the S2 subunit
or the S1/S2 proteolytic cleavage site. S1 RBD is the most
crucial target for SARS-CoV NAbs, which may interrupt
the interaction of RBD and its ACE2 receptor (Wong et
al., 2004).
Here in this review, we discuss reverse engineering
from convalescent plasma, classical hybridoma technology,
human hybridoma technology, phage display technology,
and mammalian cell surface display technology to develop
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Table. Strategies for neutralizing antibody development.
Methods

Convalescent plazma

Hybridoma

Human hybridoma

Original antibody

Mammalian display

In vitro/ in vivo
model

Ref

-

Whole virus

Duan et al.
2020; Shen
COVID-19 patients
et al. 2020;
Xinhua 2020

Human antibodies from
convalescent COVID-19
patients

-

Whole virus

Pseudotyped virus Wu et al.
neutralization assay 2020

47D11 Mouse/Human
Chimeric full antibody
against SARS-CoV

Fully human antibody

SARS-CoV-2
Pseudotyped virus
Wang et al.
Spike antigen
neutralization assay 2020
S1-S2 region

Full antibody from mouse
hybridoma

-

SARS-CoV-2
Pseudotyped virus Xiong et al.
Spike antigen
neutralization assay 2020
RBD Domain

There are no NAbs developed with this technique
Two monoclonal
antibodies (P2C-1F11 and The genes of the selected B
lymphocytes were cloned
P2B-2F6) were selected
into mammalian expression
from the B lymphocyte
system
of convalescent COVID
patients.
Single-domain antibody
Bivalent human IgG Fcfrom llama
fusion protein

Pseudotyped virus
SARS-CoV-2
and SARS-CoV-2
Ju et al. 2020
Spike antigen
virus neutralization
RBD domain
assay

Naive human scFv
antibody

SARS-CoV-2
Spike antigen
SARS-CoV-2
CDR3 Diversification by
Spike antigen
mutations
RBD
Grafting naive CDR regions RBD domain
into the framework region of and the S1
an allele in human antibody subunit of
heavy chain variable region SARS-CoV-2
SARS-CoV-2
Human IgG1 antibody (4A3)
RBD

Domain library

Fused with human Fc

Single-domain antibody

There are no NAbs developed with this technique

human antibodies, humanized antibodies and human
scFv and single domain antibodies against SARS-COV-2
(Figure). Later we provide brief summary of in vitro and
in vivo neutralizing assays including animal models for
SARS-CoV-2.
2. Convalescent plasma
Although there are many projects carried out in many
laboratories around the World, currently, there are no
approved drugs, vaccines, NAbs, or antiviral agents
targeting coronavirus, and they may not be available in
a short time (Duan et al., 2020). On the other hand, the
rising number of patients recovering from COVID-19 with
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Target region

Human antibodies from
convalescent COVID-19
patients

Synthetic human Fab
library

Phage display

Reformated antibody

Pseudotyped virus Wrapp et al.
neutralization assay 2020
Pseudotyped virus Zeng et al.
neutralization assay 2020
Pseudotyped virus Wu et al.
neutralization assay 2020

Pseudotyped virus
neutralization assay
Pseudotyped virus
SARS-CoV-2- and SARS-CoV-2
RBD
virus neutralization
assay

Liu et al.
2020
Liu et al.
2020

a high neutralizing antibody titer day by day highlights
convalescent plasma therapy as a promising alternative for
COVID-19 treatment (Chen et al., 2020).
For more than a century, convalescent plasma (CP)
therapy, which is traditional passive immunotherapy, has
been used to prevent and treat the outbreaks of many
infectious diseases which have been reviewed previously
(Casadevall and Pirofski, 2020).
Some clinical CP therapy experiments have already
been reported on SARS-CoV-2. In China, 245 COVID-19
patients received pilot convalescent plasma therapy in
February, and 91 cases demonstrated improvements in
terms of clinical indicators and symptoms. Duan et al.
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Figure. Schematic representation of different SARS-CoV-2 neutralizing antibodies described in this study.

(2020) reported the results of CP transfusion on 10 severe
adult cases confirmed by a real-time viral RNA test.
A single dose of 200 mL CP derived from 39 recovered
donors having neutralizing antibody titers above 1:640
was transfused to the patients, and their clinical symptoms
such as the oxyhemoglobin saturation, the level of
neutralizing antibodies, the lymphocyte counts and the
decrease of C-reactive were significantly improved.
Shen et al. (2020) reported another CP transfusion
study on 5 severe COVID-19 patients who were receiving
mechanical ventilation during treatment, and all of whom
had received antiviral agents and methylprednisolone.
Following the transfusion of CP with a neutralizing titer
more than 1:40, the body temperatures decreased within
3 days. Within 12 days, the SOFA scores were reduced,
the PAO2/FIO2 ratios were increased, and the viral loads
became negative. Neutralizing antibody titers of all 5
patients increased by scores ranging from 80 to 320.
For CP therapy evaluation, the level (titers) of
neutralizing antibodies against SARS-CoV-2 virus
is critical, and the plasmas containing NAbs must be
obtained from recovered patients when the titers of NAbs
reach their peak after the onset of disease. Wu et al. (2020)
screened plasma samples collected from 175 COVID-19
recovered patients using pseudotyped lentiviral vector
based neutralization assay. The domain RBD, the subunit
S1, and the subunit S2 of SARS-CoV-2 were used in ELISA
to determine the level and time-course of spike-binding

antibodies in plasma. They revealed that SARS-CoV-2
specific antibodies were detected from the day-10-15 after
the onset of disease and remained thereabouts afterward.
The titers of patients varied depending on age. Elderly and
middle-aged patients had significantly higher plasmaNAb rates (P < 0.0001) and spike-binding antibodies (P =
0.0003) than young patients.
There are also some known and theoretical risks of
passive administration of convalescent sera. Transfusion
transmitted infections (TTI), allergic transfusion reactions
like serum sickness; transfusion associated circulatory
overload (TACO), transfusion related acute lung injury
(TRALI) are the known risks of convalescent sera
transmission. While, TRALI is of particular concern in
severe COVID-19 given potential priming of the pulmonary
endothelium the risk of TRALI is less than 1/5000
transfused units. With the development of modern blood
banking methods, the risk of accidental transmission of
known infectious agents or triggering transfusion reactions
becomes very low (Casadevall and Pirofski, 2020). There
is a theoretical risk of antibody-dependent enhancement
phenomenon of infection after transfusion. ADE refers
to a process in which antibodies that target one serotype
of coronavirus could enhance infection to another viral
serotype. Wan et al. (2020), showed a novel mechanism for
ADE in which a NAb that binds coronavirus surface spike
protein like a viral receptor, activates spike conformation
and mediates viral entry into receptor-expressing IgG Fc
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cells via canonical viral receptor-dependent pathways.
Also, it is still unknown to what extent convalescent
plasma represses the development of a natural immune
response, especially when administered for prophylaxis
and makes such individuals vulnerable to reinfections.
Risk-benefit assessment must be investigated carefully
and must be supported with scientific data. Although CP
therapy is a fast and effective form of treatment that can
be applied in difficult situations, is not a real solution for
diseases. Since it is associated with the amount of antibody
titers in the blood of patients who recover, which is not an
infinite source. Therefore, reverse engineering is needed
for the development of neutralizing antibodies.
Ju et al. (2020), are the first group which characterized
206 RBD-specific human mAbs isolated from single B cells
by FACS from eight SARS-CoV-2-infected patients. They
have cloned the genes of these B cell into an expression
vector for further analysis. Then they showed the potential
binding and neutralizing effect of the antibodies by surface
plasmon resonance assay and neutralization assay with
pseudovirus and the SARS-CoV-2 virus. They found 2
potent SARS-CoV-2 neutralizing human monoclonal
antibodies (P2C-1F11 and P2B-2F6).
3. Hybridoma technology
An ideal alternative to hyperimmune sera is monoclonal
antibodies owing to their specific pharmacological
and safety profiles (Traggiai et al., 2004; Li et al., 2006).
Hybridoma technology allows the production of
monoclonal antibodies against specific target antigens, in
large quantities in the laboratory environment.
Classical hybridoma technology includes the
vaccination of mice with specific antigens and the
development of hybridoma cells by the fusion of antibodyproducing B lymphocytes and immortal myeloma cells. The
fusion merges the cytoplasms of the 2 beneficial somatic
cells with the help of a chemical agent (polyethylene glycol)
(Galfre and Milstein, 1982). Effective immunization is
essential to obtain a strong and target-specific antibody
response from mice. Immunization is done either by using
the whole/a part of an antigen or antigenic peptides for
which immunogenicity is enhanced by conjugating them
to a larger and immunogenic carrier molecules such as
KLH, BSA or ovalbumin (Fuentes, 2005; Ertekin, 2013).
B cells that produce antibodies in the spleen and lymph
nodes of animals, immunized with the target antigen, are
fused with myeloma cells to form immortal antibodyproducing cell lines. The basis of monoclonal antibody
technology is to ensure the recognition of a single epitope
and the production of antibodies by hybrid cell lines.
Therefore, the antibody activities after fusion are detected
by indirect ELISA. Selected hybridomas are subjected to 3
rounds of cloning using limited dilution method. Crossreactions are investigated by testing the antibody activity
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against similar viruses, enzymes and proteins, especially
blood serum proteins, to determine the specificity of the
antibodies
In recent studies, chimeric antibodies, containing
both human and mouse antibody sequences, have been
developed by hybridoma technology to treat and prevent
the new types of human coronavirus MERS-CoV and
SARS-CoV-2 associated diseases (Berry et al., 2004;
Widjaja et al., 2019; Wang et al., 2020).
Wang et al., 2020, screened the supernatants of 51
SARS-S hybridomas derived from immunized transgenic
H2L2 mice that encode chimeric immunoglobulins
(human variable regions and rat constant regions) against
SARS-CoV-2 S2-S1 region. Four of the supernatants
displayed cross-reactivity with the subunits S2 and S1
of SARS-CoV-2. One of these hybridoma supernatants
(47D11) revealed neutralizing activity in pseudotyped
virus neutralization assay. The chimeric 47D11 was
then reformatted into a fully human antibody. They
hypothesized that this antibody is neutralizing both SARSCoV and SARS-CoV-2 through a different binding region
than the expected RBD-ACE2 binding.
Xiong et al. (2020) reported that SARS-CoV-2 spike
RBD domain specific antibody was generated from
immunized BALB/c mouse with SARS-CoV-2 spike RBD
domain protein. With this study, mAbs against SARSCOV-2 RBD were produced using hybridoma technology.
Using neutralizing mouse antibodies developed by
the hybridoma technology may cause unfortunately the
production of antimouse antibodies in humans (HAMA).
Therefore, an antibody humanization step is necessary
to reduce HAMA responses (Kim, 2012; Safdari, 2013;
Ahmadzadeh, 2014). However, with the increased number
of convalescent patients, the development of human
mAbs from the covalescent patients has gain interest
because no HAMA response is expected and the antibody
humanization step is not needed.
There are many methods available for the development
of human monoclonal antibodies (mAbs), including the
transformation of Epstein-Barr virus (EBV), the use of
phage-display libraries, the mammalian cell systems (i.e.
CHO or NS0 transfectomas) to recombinantly produce
mAbs by the immunization of transgenic mice carrying
human Ig genes (xenomice), the molecular techniques
focused on antigen-specific B cell isolation of Ig genes and
finally the hybridoma technology. Each of these methods
has certain advantages and restrictions that determine
their use for other purposes which is described elsewhere
(Li et al., 2006; Gorny, 2012).
4. Human hybridoma technology
The human hybridoma technology is a vital tool for
production of human monoclonal antibodies. Early on,
the possibility of using human mAbs for the prevention
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or treatment of human diseases was evident and was the
driving force behind intensive effort to establish methods
for human hybridoma. For this purpose, a selection of
techniques could be used with varying efficiencies (Scott
and Crowe, 2015).
One major obstacle to the development of human
hybridomas over the years was the difficulty in collecting
antigen-specific B cells to extend target populations.
Antigen-specific memory B cells normally circulate
in the peripheral blood at low concentrations, usually
within a range centering about 1, or less, in 10,000 B cells.
Therefore, it was difficult to generate human hybridoma
cells, which would secrete desirable human mAbs. Recent
technological developments in increasing the starting
number of human antigen-specific B cells, improving the
fusion efficiency and isolating new myeloma partners, and
new cell cloning methods have allowed the development
of protocols that make it possible to isolate B cells from
blood samples and develop mAbs (Scott and Crowe, 2015).
Despite technical improvements in human hybridoma
technology, there are no available human hybridoma cell
lines developed against SARS-CoV-2.
The selection of a proper blood donor is a key to this
process. First, there may be some ethical challenges and
restrictions concerning the collection of B cells from
individuals. Special precautions must be taken about the
origins of B cells to ensure patients’ anonymity and privacy
(Scott and Crowe, 2015). Then, a high titer of serum
antibodies does not guarantee a high number of relevant
peripheral B cells, but indicates a higher chance of effective
mAb development (Gorny, 2012).
The use of unstimulated human peripheral blood
lymphocytes (B lymphocytes) in mAb production is
quite rare. On the other hand, human myeloma and
lymphoblastoid cell lines could allow mAb production
by means of fusion. Now we know how to increase the
efficiency of fusion and consequently the efficiency of mAb
production significantly by means of B-cell stimulation.
Today, there is no longer any technical limitation to
making human mAbs in the broadest sense. Biological
problems involving the determination of the type and
nature of any synthetic or natural antibody, the advantages
of different immunological compartments of B cells, and
various assays for the qualification and quantification of
mAbs have been extensively solved (Huang et al. 2020).
The most critical and challenging step in manufacturing
human hybridomas is the fusion of desired lymphocyte
populations with a myeloma partner effectively. There are
3 basic techniques used in mAb production to generate
hybridomas: the use of (i) chemical agents such as PEG,
(ii) fusogenic viruses, and (iii) electrical cytofusion. The
most popular method used to generate hybridomas takes
advantage of PEG’s fusogenic properties, while electric
cytofusion is the most effective method of generating

cell fusion and hybridoma (Wilson and Andrews, 2012;
Scott and Crowe, 2015). There are several myeloma cell
lines that are suitable for fusion with human B cells and
are available in the American Type Culture Collection
(ATCC). Two of those cell lines, SHM-D3327 and HMMA
2.5, are frequently used for development of human mAbs
(Gorny, 2012).
The final step in human hybridoma generation is the
isolation of successful fusion products in the form of
single-cell clones, which is a method also referred to as
biological cloning. (Scott and Crowe, 2015). There are
now many approaches that can be used for biological
cloning of human hybridomas. Traditionally, this was
done by limiting dilution plating. More recently, advances
in automated single-cell flow cytometric sorting, with
indexing capabilities, have allowed fast, accurate and
versatile single-cell plating. Finally, semisolid medium
preparations can be used to grow single hybridoma cells
as isolated, suspended colonies. This process can be highly
automated with special clone picking devices and can also
be carried out in an antigen-specific and semiquantitative
fashion for the selection and biological cloning of highproducing human hybridomas (Scott and Crowe, 2015).
5. Phage display technology
Phage display technology was discovered in 1985 by the
2018 Nobel prize laureate George P. Smith. He successfully
integrated a foreign DNA into a filamentous M13 phage
genome such that he could display the gene product
on the surface of the phage (Smith, 1985). Today, M13
phage has been widely used in phage display technology
applications because of its ease of use in the laboratory. It
is a virus infecting specifically E. coli bacteria. M13 phage
also differs from other phages by its unusual mechanism
of producing progeny by continually releasing new phages
from the bacterium without killing it (Nancy and Janine,
2004; Ledsgaard et al., 2018). These 2 advantages made
the M13 phage based display technology step forward
amongst other phage display technologies.
The phage display technology is based on the
integration of a gene encoding a peptide or a protein
fused with the phage coat proteins. The most extensively
used coat proteins for display are the PVIII and PIII
proteins; however, other coat proteins have also been
used for display (Smith and Petrenko, 1997). Because of
its high copy number (-2700 copies), the PVIII protein
has been only used for the display of small peptides due
to conformational problems hampering capsid formation
(Iannolo et al., 1995). The PIII system, on the other hand,
with its low copy number (5 copies), allows the display
of larger molecules such as recombinant antibodies.
The first phage display system displaying antibodies was
described by McCafferty et al. (1990). They successfully
displayed antibody variable regions on phages by using
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immunoglobulin variable genes of hybridomas and B cells.
Since then, phage display technology has been extensively
used for the discovery of antibodies or peptides against a
large variety of antigens in many fields of application such
as toxiconology (Ledsgaard et al., 2018), drug discovery
(Erdag et al., 2007; Mimmi et al., 2019), immunization
(Bahadır et al., 2011), epitope mapping (Folgori et al.,
1994) and virus or toxin neutralization (Lim et al., 2019)
by using phage peptide and antibody libraries.
Antibody libraries have been displayed on phages in
very different antibody formats. The main ones consist of
Fab domain of antibodies, single chain Fv (scFv) which
is the linear form of the variable domain of heavy and
light chains, and single domain antibodies (nanobodies).
The latter includes camelid VH domain and shark vNAR
(new antigen receptor) domain (Cheong et al., 2020).
There are 4 types of antibody phage libraries, naive library,
semisynthetic, synthetic and immune libraries (Carmen
and Jermutus, 2002). Naive libraries are generated from the
natural antibody repertoire of donors or nonimmunized
animals. Semisynthetic and synthetic libraries are
generated from low diversity natural antibody repertoires
by increasing the diversity with mutations in the CDR
(complementarity determining region). Lastly, the
immune library is generated from the antibody repertoire
of immunized animals (Erdag et al., 2011) or diseased or
vaccinated humans (Omar and Lim, 2018). The selection of
a target specific antibody from the phage libraries is made
with a method called biopanning or affinity selection. The
method consists of exposing the antibody phage library
to the target antigen which is immobilized on a solid
surface. The phages displaying antibodies specific to the
target, bind to the antigen and the nonbinders are washed
away from the media. Then the target specific phages are
recovered by elution for a phage amplification step by
infecting fresh bacterial cells. The phages are collected for
a second round of biopanning. Generally, 3–4 biopanning
cycles are sufficient to select antigen-binding antibodies
(Smith and Petrenko, 1997).
Since the COVID-19 pandemic emerged in December
2019, phage display technology has been intensively
used for the development of neutralizing antibodies.
Many different antibody libraries of different formats
and strategies have been screened against SARS-CoV-2
spike protein and its receptor binding domain (RBD).
Some of the studies have focused on screening previously
developed libraries against SARS-CoV and MERSCoV and finding cross-reactive antibodies. Others have
performed screenings against semisynthetic or synthetic
antibody libraries. Wrapp et al. (2020) reported that a
previously developed a phage displayed single-domain
antibody from llama, neutralizing the S antigen of
SARS-CoV was also neutralizing the S antigen of the
pseudotyped virus SARS-CoV-2 as a bivalent human IgG

208

Fc-fusion protein. Zeng et al. 2020, constructed a phage
displayed synthetic human Fab library (with an estimated
size of 1 × 1012). The library was screened against the
RBD domain of the SARS-CoV-2 spike antigen. They
selected 2 antibodies with high affinity to RBD, however,
only 1 showed neutralizing effect in competitive/blocking
ELISA and pseudotyped virus neutralization assay. Wu
et al. (2020) developed a phage-displayed single-domain
antibody library by grafting naive CDR regions into the
framework region of an allele in the human antibody heavy
chain variable region. They made affinity selection against
the RBD domain and the S1 subunit of SARS-CoV-2 and
chose several neutralizing antibodies, including a “cryptic”
epitope located in the spike’s trimeric interface. Liu et al.
2020, performed site-directed screening in a naive human
scFv antibody library and domain antibody library by
phage display against SARS-CoV-2 RBD. After several
rounds of screening, they obtained 9 enriched clones from
the domain antibody library and a single clone from the
scFv antibody library. The scFv clone was reformatted
into a human IgG1 antibody, while the domain antibody
clones were fused with human Fc tag. By this way, Liu
et al. revealed a potential neutralizing effect of these
recombinant antibody structures with pseudotyped virus
neutralization assay.
On the other hand, with the increasing number of
convalescent plasma uses from COVID-19 patients, the
B lymphocytes have become readily available for the
development of phage displayed human scFv and Fab
antibody libraries. To this end, we have initiated the
development of phage displayed human scFv libraries
generated from convalescent plasmas of COVID-19
patients.
6. Mammalian cell display
The basis of display technologies is the use of genotypephenotype relations. These technologies frequently use
microbial systems like phage, bacteria, and yeast. In
recent years, mammalian cell display technology has
been introduced with some advantages such as improved
efficiency in protein folding and posttranslational
modifications. Compared to other display technologies,
mammalian cell display technology comes to the fore by
allowing the scanning of functional antibody structures
and making use of FACS and in situ scanning methods.
The highlight is that the library size that can be used for
scanning is smaller than that of other systems (˂109)
(King et al., 2004).
Ho et al. (2006), transferred single chain variable
fragments (scFv) of an antibody through transient
(temporary) transfection to human embryonic kidney
cells and expressed them on the cell surface. ScFv DNA was
collected and analyzed using FACS (Ho et al., 2006) until
scFv clones with the desired specificity were identified for
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the selection of the original antibody to the target antigen
(Akamatsu et al., 2007). In the report, they showed that
all IgG antibodies could temporarily be produced on the
cell surface and cells that synthesize antibodies against the
target antigen could be selected through selection cycles
based on FACS (Akamatsu et al., 2007). Ho and Pastan
(2019), announced that scFvs could also be transferred
to the mammalian cell surface for affinity maturation. In
the abstract of the report, the strategy for isolating highaffinity scFv specific to the CD22 antigen was identified as
“mammalian cell display”. The strategy they have formed
consists of the transient expression of antibodies on 293
T (HEK-293T) human embryonic kidney cell surface
allowing clone selection by flow cytometry (Pastan et al.,
2009).
Zhou et al., 2010, reported the display of full size
IgGs on CHO cell surface. An important feature of the
developed library was that recombinant DNA transfection
was performed to include a single antibody replica gene
in the genome of each cell. The use of the gene integration
zone allowed the comparison of clones by a signal point.
Along with the FACS system, this function proved to be
capable of screening clones with high affinity and a high
expression rate.
Mammalian cell screening technology can also be
used for antibody-based drug development for COVID-19
treatment. For this purpose, VH and VL antibody libraries
can be generated with the blood samples of COVID-19
patients. Then, the libraries generated can be screened in
mammalian cells against COVID-19 antigens (Beerli et
al., 2008). Up to our knowledge mammalian cell screening
hasn’t been applied for the development of NAbs for
SARS-Cov-2.
7. In vitro bioassays
Once NAbs are developed, it is vital to test them for their
neutralizing efficiency. In other words, it is crucial to show
that the virus, which has the power to create an infection,
is effectively eliminated/neutralized by in vitro and in vivo
systems. To this end, easy and safe screening methods –
like ELISA and surface plasmon resonance (SPR)– could
be helpful in decreasing the number of NAbs to be tested
in neutralization assays. These screening methods would
give an idea about the blocking capability of the NAbs on
the viral spike protein and ACE2 interaction. Thus, the
neutralization assays would be concentrated on the most
potent NAbs.
7.1. Plaque reduction neutralization test- (PRNT)
Plate-reduction neutralization test is used to titer
neutralizing antibody for a virus. The serum or antibody
to be screened is diluted and combined with a viral
suspension. The antibody is incubated with the isolated
virus and then transferred on host adhering cells. The
surface of the cell layer is coated with a layer of agar or

carboxymethyl cellulose to prevent the indiscriminate
spread of the virus (Schmidt et al., 1976). The concentration
of plaque-forming units can be estimated by the number
of plaques (regions of infected cells) formed after a few
days. Depending on the virus, the plate builder units may
be determined through microscopic examination, or with
specific dyes that react with fluorescent antibodies or
infected cells. The concentration of serum indicates how
many antibodies are detected or how effective it is in the
reduction of the number of plaques by 50% compared to
the serum-free virus. This calculation is defined as the
value of PRNT50.
Currently, PRNT50 is considered to be the “gold
standard” to detect and measure antibodies that can
neutralize viruses. It has a higher sensitivity than other
tests, such as hemagglutination and many commercial
Enzyme immunoassays. It is also more specific for the
diagnosis of some arboviruses than other serological
methods (Ratnam et al., 2009; Stephen et al., 2009).
One problem with this recently defined test is that
the neutralizing ability of antibodies depends on virion
maturation state and the type of cell used in the test.
Therefore, if the wrong cell line is used for the analysis,
the antibodies may appear to be effective in neutralization
even if they are not in fact, or vice versa.
7.2. Virus neutralization assay
Virus neutralization assay is used in combination with an
infection experiment, such as PRNT. This assay detects a
neutralizing antibody that can stop virus replication. Sera
or culture supernatants are diluted and mixed with the
virus (the virus titer can be determined per PRNT50, etc.).
The mixtures are incubated approximately for 45 minutes
at room temperature, and then the mixture is added on
suitable cell lines (Vero, Vero6, etc.) and the cells are
incubated for 3 days at 37 °C (Traggiai et al., 2004; Xiong
et al., 2020).
In a standard CPE (cytopathic effects) assay, a
monolayer of cells is infected with a virus and then
monitored for several days (or weeks) of morphological
changes. The changes are expressed in distinct points
corresponding to the sites of infection. Plaque assay has
been the method of choice for several decades, where,
shortly after the infection, the monolayer of cells is
overlaid with semisolid material such as agarose. There
are some variations in the plaque assays (with or without
staining cells, for example), however, all of them are
labour-intensive, human dependent and hands-on jobs;
thus, the determination of CPE is difficult. Therefore,
it would be helpful to opt for using a more efficient and
higher throughput alternative to traditional CPE assays: a
real-time cell analysis (RTCA) system which is based on
electric cell-substrate impedance sensing technology that
can monitor cytopathic effects.
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8. In vivo neutralization assays
In vaccine and drug research, preclinical studies must be
conducted on animals. The efficacy of a candidate vaccine
or drug is investigated first on mice, and then gradually
on larger animals. The most critical stage on the way to
a product is in vivo challenge experiments. To this end,
the candidate molecule is given to mice with target
microorganism and its effectiveness is tested. During
the global fight with SARS-CoV-2, vaccine and drug
development studies have gained a momentum. However,
there are not much in vivo results for this virus in the
literature yet. On the other hand, model animal studies
were conducted on MERS-CoV and SARS-CoV diseases
that caused infections in the past years. Therefore, in vivo
studies of these viruses from the same family as SARSCoV-2 will constitute a reference for new studies.
8.1. Mouse model
Unfortunately, common small laboratory animals
such as mice, ferrets, guinea pigs and hamsters were
found not susceptible to MERS-CoV infection; because
MERS-CoV receptor dipeptidyl peptidase-4 (DPP4) is
a multifunctional transmembrane endopeptidase that
breaks down insulin and other peptide hormones. For this
reason, hDPP4 transgenic mouse model was created with
C57BL/6 mice for MERS-CoV infection (Luke et al., 2016;
Zhao et al., 2018; Li and McCray, 2020).
Studies revealed that several inbred species of the
mouse (BALB / C, C57BL/6, B6, 129S) promote replication
of SARS-CoV, creating clinical symptoms of pneumonitis
(129S) and SARS (aged BALB/C) (Glass et al., 2004; Hogan
et al., 2004; Subbarao et al., 2004; Roberts et al., 2005a).
In mice immunized with SARS-CoV, the peaks of
the virus titer in lungs occur at days 2–3 postinjection.
However, at days 5–7 postinjection, the virus is cleared in
most mice (Roberts et al., 2008). In young mice, replication
of SARS-CoV is not specifically associated with clinical
symptoms and pathology of the disease. However, 129S6
mice were found to be more susceptible to SARS-CoV
infection than BALB/C or B6 mice, with weight loss and
early onset of pneumonia (Hogan et al., 2004; Roberts et
al., 2008).
In BALB/C mice, old ones experience a more severe
disease, which results in increased mortality, than young
ones, just like the case in SARS-CoV infection in humans
(Roberts et al., 2005a). Therefore, being susceptible
to age-related factors in diseases, aged BALB/C mice
might also be an ideal animal model for SARS-CoV
studies. The clinical symptoms of BALB/C mice include
weight loss, dehydration, fur structure deterioration and
histopathological damages such as viral replication in
respiratory tissues and pneumonia (Roberts et al., 2005a;
Roberts et al., 2008).
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Roberts et al. (2008) investigated the susceptibility of
various types of aged mice to SARS-CoV infection. They
reported significant weight losses by aged B6, 129S6 (12–
14 months) and BALB/C mice at days 3–5 postinjection
being immunized with 105 TCID50 SARS-CoV (Urbani
strain) (Roberts et al., 2005a). The same study also
revealed similar results in terms of viral replication levels
and kinetics in the lungs of aged B6 and BALB/C mice. At
days 5 and 6 postinjection, B6 mice infected with SARSCoV were observed to have 10–70 times lower virus titers
than BALB/C mice (Roberts et al., 2008).
The referred publications indicate that the mouse
models for SARS with these animals, except for aged or
immunocompromised ones, did not develop significant
clinical symptoms or reasonable mortality rates. For this
reason, in recent studies, a new transgenic mouse model
has been introduced to mimic human disease, to conduct
pathogenesis studies and to develop antiviral treatments for
SARS: K18-hACE2 transgenic mice, which express human
ACE2, the receptor used by SARS-CoV (McCray et al.,
2007). It has been shown that the K18-hACE2 transgenic
mouse model may also be useful in studies on the outbreak
and pathogenesis of the disease by novel coronavirus-2019
(SARS-CoV-2). In this context, Linlin et al. (2020) have
studied hACE2 transgenic and wild-type (WT) mice to
investigate SARS-CoV-2 virus pathogenicity.
Challenge studies should be done carefully in animal
bioSafety level-3 (ABSL-3) laboratories with personal
protective equipment. To conduct a challenge study, the
median lethal dose (LD50) of the infectious agent to be
resisted must be known. Although Day et al. (2009)
conducted studies on the median lethal dose in BALB/C
mice using various SARS-CoV virus strains; regarding
SARS-CoV-2, no literature is available on such studies, yet.
Therefore, as a precursor of the median lethal dose, in
vitro studies should be started to determine the median
tissue culture infectious dose (TCID50). Day et al. (2009)
studied 3 different SARS-CoV virus strains (v2163, MA15
and Urban) with 3 different (103.5, 104.5, 105.5) median
tissue culture infection doses (TCID50) in BALB/C mice.
They observed the effects of these strains with different
virulence factors on young and aged BALB/C through
a 21-day challenge experiment. The survival rates of
the animals per infection dose they received at different
postinjection times and survival between the days of the
defect were determined, and the virus titers in the lungs
of the sacrificed animals were compared (Barnard et al.,
2006; Roberts et al., 2007; Day et al., 2009). These studies
revealed that the hypotheses on the median tissue culture
infection doses (103.5, 104.5, 105.5) were valid for SARSCoV (Day et al., 2009). Even if these doses are already
determined, it is needed to conduct similar studies on
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animals to better calculate the virulence factor in terms of
SARS-CoV-2.
8.2. Other animal models
8.2.1. Golden Syrian hamsters
The golden Syrian hamster is an excellent model for SARSCoV infection because viral replication is accompanied by
pathological changes in the lungs including pneumonitis
(Roberts A et al., 2005b). Following intranasal inoculation
with 103 TCID50 SARS-CoV, hamsters support viral
replication in the nasal turbinates and lungs. Viremia
is detected at days 2-3 post-injection, and the virus can
be recovered from the spleen and liver (Roberts et al.,
2008). Although the disease produces histopathological
symptoms in hamsters, clinical symptoms are not evident.
The most striking example of this is reduced night
movements in 5-10-week-old hamsters infected with
SARS-CoV.
8.2.2. Ferrets
Another disease that causes lung infection is influenza
(H1N1). The model animal used in the vaccine studies
of this disease is ferret. Studies have been conducted with
these animals for SARS-CoV infection, which has the
same target organ destruction.
It has been demonstrated that Ferrets support SARSCoV replication and develop multifocal pulmonary
lesions that contain 5%–10% of the lungs’ surface area (Ter
Meulen et al., 2004). It was determined that populations
immunized with 103 or 104 TCID50 SARS-CoV caused
virus replication in the lungs at 106 TCID50/mL on the
fourth day (Martina et al., 2003; Ter Meulen et al., 2004).
Compared to other vaccine studies for SARS-CoV, this
model revealed poor efficacy. Therefore, more studies were
needed to understand its immunogenicity (Bisht et al.,
2004; Chen et al., 2005).
8.2.3. Nonhuman primates (NHP)
Nonhuman primates (NHPs) support viral replication
and pneumonitis with variable clinical symptoms and
pathology, depending upon the species. Various strains of
SARS-CoV were tested on rhesus macaques (McAuliffe et
al., 2004; Rowe et al., 2004; Qin et al., 2005), cynomolgus
macaques (Kuiken et al., 2003; Lawler et al., 2006),

common marmosets (Greenough et al., 2005), African
green monkeys (McAuliffe et al., 2004), squirrel monkeys
and mustached tamarins. Studies revealed that squirrel
monkeys and mustached tamarins are not susceptible to
SARS-CoV Urbani infection. Among nonhuman primate
models, rhesus and cynomolgus macaques were found to
be the best NHPs in SARS-CoV studies.
Sinovac Biotech Ltd. (Beijing, China), a biotechnology
company, has conducted a study on the protection of
macaque monkeys from infection by SARS-CoV-2 by
a vaccine candidate and announced that they attained a
positive result. It is sure that the number of NHP studies
will increase in vaccine development studies against the
novel coronavirus-2019 (SARS-CoV-2) pandemic.
9. Conclusion
Since the first detection of the novel coronavirus-2019
(SARS-CoV-2) in the Wuhan City of China in December
2019, researchers from all over the world are investigating
and collaborating for the determination of the virus
structure and its mode of infection in order to find a
treatment against COVID-19 and a vaccine for a longer
protection. The experience from previous virus epidemics
indicate that cocktail of neutralizing antibodies are
promising for a stronger virus neutralization. Therefore, it
is important to discover several antibodies able to block
the virus, and this variety can be achieved by the use of
various antibody development technologies.
Cocktail of NAbs has displayed a stronger
neutralization than alone in treating both Ebola and SARS
viruses. The generation of NAbs targeting various epitopes
on SARS-CoV-2 would indeed be very important. In this
way, combining a number of potent NAbs might reduce
the possibility of the emergence of mutant strains.
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